These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
22. Early idiopathic parkinsonism: initiation and optimization of treatment. Calne DB Clin Neuropharmacol; 1994; 17 Suppl 2():S14-8. PubMed ID: 9358191 [TBL] [Abstract][Full Text] [Related]
23. Subthalamic GAD gene transfer in Parkinson disease patients who are candidates for deep brain stimulation. During MJ; Kaplitt MG; Stern MB; Eidelberg D Hum Gene Ther; 2001 Aug; 12(12):1589-91. PubMed ID: 11529246 [TBL] [Abstract][Full Text] [Related]
24. The effect of deprenyl and levodopa on the progression of Parkinson's disease. Olanow CW; Hauser RA; Gauger L; Malapira T; Koller W; Hubble J; Bushenbark K; Lilienfeld D; Esterlitz J Ann Neurol; 1995 Nov; 38(5):771-7. PubMed ID: 7486869 [TBL] [Abstract][Full Text] [Related]
28. Impact of sustained deprenyl (selegiline) in levodopa-treated Parkinson's disease: a randomized placebo-controlled extension of the deprenyl and tocopherol antioxidative therapy of parkinsonism trial. Shoulson I; Oakes D; Fahn S; Lang A; Langston JW; LeWitt P; Olanow CW; Penney JB; Tanner C; Kieburtz K; Rudolph A; Ann Neurol; 2002 May; 51(5):604-12. PubMed ID: 12112107 [TBL] [Abstract][Full Text] [Related]
29. L-deprenyl in the treatment of Parkinson's disease. Csanda E; Tárczy M; Takáts A; Mogyorós I; Köves A; Katona G J Neural Transm Suppl; 1983; 19():283-90. PubMed ID: 6421993 [TBL] [Abstract][Full Text] [Related]
30. The effects of early selegiline therapy on long-term levodopa treatment and parkinsonian disability: an interim analysis of a Norwegian--Danish 5-year study. Norwegian-Danish Study Group. Larsen JP; Boas J Mov Disord; 1997 Mar; 12(2):175-82. PubMed ID: 9087975 [TBL] [Abstract][Full Text] [Related]
33. ["Widening horizons" in the clinical application of selegiline]. Kovács A Acta Pharm Hung; 1992 Sep; 62(5):259-64. PubMed ID: 1488911 [TBL] [Abstract][Full Text] [Related]
34. An analysis of treatment options and outcome in patients with Parkinson's disease and severe dyskinesias. Mark MH; Sage JI Ann Clin Lab Sci; 1994; 24(1):12-21. PubMed ID: 8147565 [TBL] [Abstract][Full Text] [Related]
35. R-(-)-deprenyl as a possible protective agent in Parkinson's disease. Tetrud JW; Langston JW J Neural Transm Suppl; 1987; 25():69-79. PubMed ID: 3123606 [TBL] [Abstract][Full Text] [Related]